Cabaletta Bio
Yahoo Finance • 2 months ago
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for pati... Full story
Yahoo Finance • 5 months ago
SA Quant ranks Goldman's small-cap stocks with largest short interest
[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap st... Full story
Yahoo Finance • 5 months ago
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phas... Full story
Yahoo Finance • 5 months ago
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
The dynamics of the CAR T-cell therapy market are anticipated to change due to the extensive R&D activities, an increase in investment for research and development of the new CAR T-cell therapy, such as zamtocabtagene autoleucel (Miltenyi... Full story
Yahoo Finance • 6 months ago
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering s... Full story
Yahoo Finance • 8 months ago
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development progra... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism
Cabaletta Bio, Inc. (NASDAQ:CABA), with a market capitalization of $106.17 million, is at the forefront of developing CAR-T therapies for autoimmune diseases, presenting a unique investment opportunity in the biotechnology sector. Accordin... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio Launches Public Offering Of Stock And Warrants
(RTTNews) - Cabaletta Bio, Inc. (CABA), a clinical-stage biotech firm developing targeted cell therapies for autoimmune diseases, has initiated an underwritten public offering of its common stock and accompanying warrants. Certain investo... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio announces pricing of public offering of securities; shares decline over 28%
* Cabaletta Bio (NASDAQ:CABA [https://seekingalpha.com/symbol/CABA]) announced on Wednesday the pricing of an underwritten public offering consisting of 39.2 million shares of its common stock and accompanying warrants to purchase an agg... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio Announces Pricing of Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies desi... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio Announces Proposed Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies desi... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding pati... Full story
Yahoo Finance • 10 months ago
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients w... Full story
Yahoo Finance • last year
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2... Full story
Yahoo Finance • last year
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these... Full story
Yahoo Finance • last year
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical develo... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-20... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
